SG Americas Securities LLC increased its position in shares of AstraZeneca plc (NYSE:AZN) by 7.7% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 135,398 shares of the company’s stock after purchasing an additional 9,686 shares during the period. SG Americas Securities LLC’s holdings in AstraZeneca were worth $6,035,000 at the end of the most recent quarter.
Several other hedge funds have also recently added to or reduced their stakes in the stock. Daiwa Securities Group Inc. bought a new stake in shares of AstraZeneca in the 3rd quarter valued at about $5,074,000. Kornitzer Capital Management Inc. KS raised its stake in shares of AstraZeneca by 48.1% during the 3rd quarter. Kornitzer Capital Management Inc. KS now owns 83,100 shares of the company’s stock worth $3,704,000 after acquiring an additional 27,000 shares in the last quarter. Parallel Advisors LLC raised its stake in shares of AstraZeneca by 10.7% during the 3rd quarter. Parallel Advisors LLC now owns 11,636 shares of the company’s stock worth $519,000 after acquiring an additional 1,125 shares in the last quarter. Cullen Frost Bankers Inc. raised its stake in shares of AstraZeneca by 24.1% during the 3rd quarter. Cullen Frost Bankers Inc. now owns 280,996 shares of the company’s stock worth $12,524,000 after acquiring an additional 54,488 shares in the last quarter. Finally, Synovus Financial Corp raised its stake in shares of AstraZeneca by 28.6% during the 3rd quarter. Synovus Financial Corp now owns 91,179 shares of the company’s stock worth $4,060,000 after acquiring an additional 20,261 shares in the last quarter. 17.54% of the stock is owned by hedge funds and other institutional investors.
Several research analysts recently commented on AZN shares. JPMorgan Chase & Co. reiterated a “buy” rating on shares of AstraZeneca in a research note on Friday. Liberum Capital upgraded shares of AstraZeneca from a “hold” rating to a “buy” rating in a research note on Friday, October 25th. Argus boosted their price objective on shares of AstraZeneca to $50.00 and gave the stock a “buy” rating in a research note on Wednesday, August 14th. HSBC reiterated a “sell” rating on shares of AstraZeneca in a research note on Thursday, October 17th. Finally, Zacks Investment Research downgraded shares of AstraZeneca from a “strong-buy” rating to a “hold” rating and set a $49.00 target price on the stock. in a research report on Thursday, October 3rd. Four investment analysts have rated the stock with a sell rating, five have given a hold rating and fourteen have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $46.53.
AstraZeneca (NYSE:AZN) last released its earnings results on Thursday, October 24th. The company reported $0.50 earnings per share for the quarter, topping the consensus estimate of $0.45 by $0.05. The company had revenue of $6.13 billion for the quarter, compared to the consensus estimate of $6.07 billion. AstraZeneca had a net margin of 8.42% and a return on equity of 38.63%. AstraZeneca’s revenue was up 14.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.71 EPS. On average, equities analysts predict that AstraZeneca plc will post 1.81 earnings per share for the current year.
In related news, major shareholder Plc Astrazeneca bought 425,000 shares of the company’s stock in a transaction on Monday, October 7th. The shares were bought at an average price of $19.00 per share, with a total value of $8,075,000.00. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink.
AstraZeneca Company Profile
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Featured Article: What type of investment options does a Roth IRA provide?
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca plc (NYSE:AZN).
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.